KMWM
ALXN

Keudell/Morrison Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Keudell/Morrison Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,287
Closed -$201K – 174
2020
Q4 		$201K Buy
+1,287
New +$165K 0.13% 152

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Keudell/Morrison Wealth Management's ALXN Position: Q1 2021 in Review

Keudell/Morrison Wealth Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 1,287 shares — an estimated $201K sold.

Keudell/Morrison Wealth Management first reported a position in ALXN in Q4 2020 and held it in 1 quarter. The position peaked at $201K in Q4 2020. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Keudell/Morrison Wealth Management reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Keudell/Morrison Wealth Management sold 1,287 Alexion Pharmaceuticals shares in Q1 2021, an estimated $201K.
  • Keudell/Morrison Wealth Management first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Keudell/Morrison Wealth Management's Alexion Pharmaceuticals position peaked at $201K in Q4 2020.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Keudell/Morrison Wealth Management's 13F filing for Q1 2021, filed 13 Apr 2021.